{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:06:56Z","timestamp":1788052016000,"version":"build-2784847793"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008668","name":"Shorai Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21lm0203002"],"award-info":[{"award-number":["21lm0203002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020912","name":"King Faisal University","doi-asserted-by":"publisher","award":["KFU254489"],"award-info":[{"award-number":["KFU254489"]}],"id":[{"id":"10.13039\/501100020912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007434","name":"Suzuken Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012834","name":"Gifu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012834","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118649","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:54:20Z","timestamp":1770364460000},"page":"118649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synthesis of potent human DHRS11 inhibitors and their efficacy against androgen-dependent proliferation and sensitivity to AKT inhibitor Capivasertib of triple-negative breast cancer cells"],"prefix":"10.1016","volume":"307","author":[{"given":"Yuri","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakana","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Tanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Toyooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Kandeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutada","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-9672","authenticated-orcid":false,"given":"Satoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118649_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118649_bib2","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejmech.2026.118649_bib3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African\u2013American and Caucasian patients","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.118649_bib4","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118649_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118649_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103197","article-title":"Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: a systematic review of clinical trials","volume":"157","author":"Ali","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.118649_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118649_bib8","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118649_bib9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118649_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cen.14710","article-title":"Approach to androgen excess in women: clinical and biochemical insights","volume":"97","author":"Cussen","year":"2022","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118649_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jsbmb.2014.06.001","article-title":"All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause","volume":"145","author":"Labrie","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118649_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mce.2016.08.014","article-title":"A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids","volume":"441","author":"Pretorius","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118649_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159867","article-title":"11-Ketotestosterone and 11-Ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can No longer be ignored","volume":"11","author":"Pretorius","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118649_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1210\/jc.2016-3285","article-title":"11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome","volume":"102","author":"O'Reilly","year":"2017","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118649_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jsbmb.2018.06.013","article-title":"11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): implications for castration resistant prostate cancer","volume":"183","author":"Barnard","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118649_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105586","article-title":"Human dehydrogenase\/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: substrate and reaction specificity in the reduction of 11-keto-C(19)-steroids","volume":"199","author":"Endo","year":"2020","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118649_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbrc.2016.01.190","article-title":"Human dehydrogenase\/reductase (SDR family) member 11 is a novel type of 17\u03b2-hydroxysteroid dehydrogenase","volume":"472","author":"Endo","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.118649_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cbi.2019.03.026","article-title":"Rabbit dehydrogenase\/reductase SDR family member 11 (DHRS11): its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11","volume":"305","author":"Endo","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.118649_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2025.109692","article-title":"Kobochromone A, a polyphenol in Carex kobomugi, suppresses androgen signaling induced by 11-oxygenated androgens and enhances the efficacy of AKT inhibitors in triple-negative breast cancer cells","volume":"223","author":"Tanio","year":"2025","journal-title":"Steroids"},{"key":"10.1016\/j.ejmech.2026.118649_bib20","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of Phosphatidylinositol-3-Kinase pathway alterations across 19 784 diverse solid tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2026.118649_bib21","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","article-title":"The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate","volume":"273","author":"Maehama","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118649_bib22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/life11111247","article-title":"Role of PTEN, PI3K, and mTOR in triple-negative breast cancer","volume":"11","author":"Prvanovi\u0107","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2026.118649_bib23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","article-title":"Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial","volume":"82","author":"Crabb","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2026.118649_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118649_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-021-06143-5","article-title":"Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced\/metastatic triple-negative breast cancer","volume":"189","author":"Dent","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2026.118649_bib26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clgc.2023.01.001","article-title":"Safety profile of ipatasertib plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer","volume":"21","author":"Matsubara","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ejmech.2026.118649_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","article-title":"Capivasertib: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118649_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","article-title":"The emerging role of capivasertib in breast cancer","volume":"63","author":"Andrikopoulou","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejmech.2026.118649_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106574","article-title":"Involvement of porcine and human carbonyl reductases in the metabolism of epiandrosterone, 11-oxygenated steroids, neurosteroids, and corticosteroids","volume":"243","author":"Endo","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118649_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214356","article-title":"Antiandrogenic effects of a polyphenol in Carex kobomugi through inhibition of androgen synthetic pathway and downregulation of androgen receptor in prostate cancer cell lines","volume":"23","author":"Kudo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118649_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118649_bib31","article-title":"Complex impacts of PI3K\/AKT inhibitors to androgen receptor gene expression in prostate cancer cells","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118649_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neo.2020.07.002","article-title":"A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo","volume":"22","author":"Zhao","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2026.118649_bib33","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/bcr2858","article-title":"Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer","volume":"13","author":"Naderi","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118649_bib35","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/0008-5472.CAN-21-2035","article-title":"Can improved use of biomarkers alter the fate of PI3K pathway inhibitors in the clinic?","volume":"81","author":"Erickson","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118649_bib36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118649_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/BJ20081682","article-title":"Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization","volume":"417","author":"Iorns","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.118649_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118649_bib39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/01.cej.0000228413.06471.4c","article-title":"Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation","volume":"16","author":"Alkhalaf","year":"2007","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.ejmech.2026.118649_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lfs.2018.07.027","article-title":"Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction","volume":"208","author":"Jia","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.118649_bib41","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3390\/ijms20133143","article-title":"Antitumor and anti-invasive effect of apigenin on human breast carcinoma through suppression of IL-6 expression","volume":"20","author":"Lee","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118649_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153437","article-title":"Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT\/mTOR signaling pathway","volume":"81","author":"Wu","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.118649_bib43","article-title":"Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase","author":"Huang","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2026.118649_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1530\/ERC-10-0204","article-title":"Androgen receptor levels are upregulated by Akt in prostate cancer","volume":"18","author":"Ha","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118649_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29655-0","article-title":"Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors","volume":"13","author":"Savill","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118649_bib46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejmech.2019.05.053","article-title":"Design, synthesis and biological evaluation of chalcones as reversers of P-glycoprotein-mediated multidrug resistance","volume":"180","author":"Yin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118649_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2017.04.023","article-title":"Human carbonyl reductase 1 participating in intestinal first-pass drug metabolism is inhibited by fatty acids and acyl-CoAs","volume":"138","author":"Hara","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118649_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109519","article-title":"Artepillin C overcomes apalutamide resistance through blocking androgen signaling in prostate cancer cells","volume":"735","author":"Ota","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2026.118649_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jmgm.2005.04.004","article-title":"Similarities among receptor pockets and among compounds: analysis and application to in silico ligand screening","volume":"24","author":"Fukunishi","year":"2005","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2026.118649_bib50","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1021\/acs.jcim.5b00319","article-title":"Computational Study of drug binding affinity to influenza A neuraminidase using Smooth Reaction Path Generation (SRPG) method","volume":"55","author":"Nguyen","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118649_bib51","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"3rd, Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118649_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jb\/mvab025","article-title":"Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells","volume":"170","author":"Endo","year":"2021","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejmech.2026.118649_bib53","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118649_bib54","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1021\/acs.jmedchem.1c02113","article-title":"Discovery and structure-based optimization of novel Atg4B inhibitors for the treatment of castration-resistant prostate cancer","volume":"65","author":"Kudo","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118649_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jb\/mvaf022","article-title":"Inhibition of autophagy by Atg7 knockdown enhances chemosensitivity in gemcitabine\/paclitaxel-resistant pancreatic cancer MIAPaCa2 cells","volume":"178","author":"Kudo","year":"2025","journal-title":"J. Biochem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:10:53Z","timestamp":1777529453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":55,"alternative-id":["S0223523426000942"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118649","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of potent human DHRS11 inhibitors and their efficacy against androgen-dependent proliferation and sensitivity to AKT inhibitor Capivasertib of triple-negative breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118649"}}